YongTai (7066) vs Bintai (6998) / Solution (0093) / Ucrest (0005) /

MYEG (0138)

Let's study the share price fluctuations of companies  involved to bring in the next vaccine to Malaysia (after Pfizer, AstaraZeneca, Sinovac). Apart from YongTai, we will take into account four other companies which are still active in their vaccine ventures.

Bintai (6998) / Solution (0093) / Ucrest (0005) / MYEG (0138)

So, how did the share price of these companies changed with each announcement?

Bintai (6998)

Solution (0093)

Ucrest (0005)

MYEG (0138)

YongTai (7066)

The table below summarizes the price hike, percentage and current share prices as of 14th June 2021, of the five companies.

YongTai's share price is indeed relatively lower in comparison to the rest. Along with Ucrest, YongTai's share price have yet to see much upside. As discussed by many, YongTai is still undervalued with bullish potential.

Some of the prominent articles seen at YongTai's forum which supports the claim:

https://klse.i3investor.com/blogs/sujibaby_yongtai/2021-06-11-story-h1566165502-Technical_Analysis_June_2021.jsp

https://klse.i3investor.com/blogs/sujibaby_yongtai/2021-06-13-story-h1566195354-YongTai_7066_Vaccine_Distribution_Prospects.jsp

https://klse.i3investor.com/blogs/thomaszum/2021-06-03-story-h1566043547-YongTai_Berhad_7066_vs_Foresight_of_the_vaccine_market_Part_1.jsp

It is interesting to note that the share price fluctuation tells a completely different story in comparison to the fundamentals of the companies. Lets take a glance on the curent fundamentals according to the latest available numbers.

YongTai's attractive NTA and P/B ratio further evidences its current undervalued position. With its high-end tourism and leisure orientated property development projects, backed by its gold-mining project, the projected revenue from its vaccine venture is expected to boost its EPS soon.

Trade Safe!

Disclaimer: The above analysis is intended solely for informational and educational purpose for peers and, should not be used as a basis for making any specific investment, business or commercial decision. Any decisions to place trades in the financial markets, including trading in stock or options or other financial instruments, is a personal decision that should only be made after thorough research, including a personal risk and financial assessment, and the engagement of professional assistance to the extend one believe its necessary.